Teva's AJOVY Receives FDA Approval for the Treatment of Migraine in Adults with Monthly and Quarterly Dosing
Shots:
- AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine- administering AJOVY alone and in combination with oral preventive treatments- showing reduction in monthly migraine days in 12 wks. duration having injection site reactions as adverse effects
- The US Wholesale Acquisition Cost (WAC) of AJOVY for monthly and the quarterly dose is $575 & $1-725 respectively- will be available within two weeks
- AJOVY SC injection will be marketed as 225 mg/1.5mL single dose in a prefilled syringe having two dosage options 225 mg/monthly as one SC IV- or 675 mg q3months as three SC IV
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
